



Pharmaceutical POOL

Lonnel COATS

Eisai Names CEO for U.S. Subsidiary



Eisai Inc., a U.S. subsidiary of Japan's Eisai Co., has promoted Lonnel Coats to president and CEO, from president and chief operating officer. In addition, Mr. Coats has been appointed senior VP of Eisai Co.'s pharmaceuticals business in the United States, responsible for leading Eisai's global medical and marketing division. Mr. Coats succeeds Hajime Shimizu, who has been appointed president of new markets at Eisai Co.

Dr. Michael EHLERS

Pfizer Selects Former Investigator as Neuroscience Research Chief



Global pharmaceutical company Pfizer has appointed Michael Ehlers, M.D., Ph.D., chief scientific officer for neuroscience research. Dr. Ehlers most recently served as the George Barth Geller Professor in the Department of Neurobiology at Duke University and as an investigator with the Howard Hughes Medical Institute.

Dr. Rajesh GUPTA

Biocodex USA Adds Medical Affairs Director

Biocodex USA, a pharmaceutical company focused on marketing niche products that tar-



get unmet medical needs, has named Rajesh Gupta, M.D., director of medical and scientific affairs. Dr. Gupta has primary responsibility for advancing Biocodex's flagship probiotic products, Florastor and Florastor Kids. In addition, Dr. Gupta is leading efforts to expand the Biocodex USA portfolio of products.

Dr. Gupta's experience includes five years as a science and policy advisor for the World Health Organization, and he most recently worked with Google's Predict and Prevent Initiative, where he focused on building the genomics strategy for emerging infectious disease initiatives. He received a master of science and a doctor of medicine from Stanford University, as well as a master of public health from Yale University.

Biotechnology POOL

Dr. Robert BRENNER

AlloCure Appoints New CEO



AlloCure, a biotechnology company pioneering the use of cell therapies for the treatment of kidney diseases, has named Robert Brenner, M.D., president and CEO. As CEO, Dr. Brenner succeeds John Wirthlin, who has assumed the position of chief operating officer and remains a member of the company's management team.

Dr. Brenner was previously senior VP of medical affairs at Amag Pharmaceuticals. He received an M.D. from Albert Einstein College of Medicine and completed a fellowship in nephrology at Stanford University Medical Center.

Dr. Timothy CLACKSON

Dr. Pierre DODION

Dr. Frank HALUSKA

Ariad Shuffles R&D Leadership

Ariad Pharmaceuticals, a biotechnology company focused on cancer, has named Chief Scientific Officer Timothy Clackson, Ph.D., to the additional role of president of research and development, with responsibility for establishing an integrated R&D organization from early discovery through advanced clinical development. He also continues to oversee manufacturing operations and program and alliance management.

Dr. Clackson has served as Ariad's senior VP and chief scientific officer since September 2003. He received a Ph.D. in biology from the University of Cambridge.

In other moves, Ariad has promoted Pierre Dodion, M.D., to senior VP, corporate development, with initial focus on partnering AP24534. Dr. Dodion has been with Ariad for three years, most recently heading clinical development and medical affairs.

Frank Haluska, M.D., Ph.D. has been named VP, clinical research and development and chief medical officer. Dr. Haluska is overseeing the pivotal trial of AP24534 in patients with resistant and refractory chronic myeloid leukemia, which is scheduled to begin patient enrollment in the second half of this year.

James CONNOLLY

Aeras Selects Former Wyeth VP as CEO

The Aeras Global TB Vaccine Foundation, a nonprofit research organization developing new tuberculosis vaccines and ensuring distribution to people in need worldwide, has named James Connolly president and CEO. Mr. Connolly joins Aeras from Wyeth Vaccines, where he most recently served as executive VP and general manager.

Dr. Douglas KARGMAN

Acorda Appoints Head of Drug Safety

Acorda Therapeutics, a biotechnology company developing therapies for multiple





sclerosis, spinal cord injury, and other nervous system disorders, has appointed Douglas Kargman, M.D., VP of drug safety, with responsibility for overseeing Acorda's drug safety and risk management programs. Dr. Kargman was previously head of benefit risk management at Novartis Vaccines and Diagnostics. He received an M.S. in epidemiology from the Columbia University School of Public Health and an M.D. from the State University of New York (SUNY) Stony Brook School of Medicine.

Dean **MITCHELL**

Lux Biosciences Hires CEO



Lux Biosciences, a privately held biotechnology company focused on the treatment of ophthalmic diseases, has appointed Dean Mitchell president and CEO. Mr. Mitchell was previously president and CEO of Alpharma. He received an MBA from City University Business School in London.

Dr. George **SCANGOS**

Biogen Idec Appoints CEO



Biogen Idec, a global biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative therapies, has named George Scangos, Ph.D., CEO. Dr. Scangos joins Biogen Idec from Exelixis, where he had served as president and CEO since 1996. He holds a Ph.D. in microbiology from the University of Massachusetts.

Dr. Sunita **SHETH**

Tengion Strengthens Clinical Leadership



Tengion has appointed Sunita Sheth, M.D., chief medical officer, VP clinical and regulatory affairs. Dr. Sheth is responsible for developing clinical development strategies for the clinical-stage biotechnology company, which is working to harness the body's natural regenerative power to grow new organs and tissues by making them from a patient's own cells.

Before joining Tengion, Dr. Sheth served as VP, specialty care business unit, for Pfizer as part of its acquisition of Wyeth. She received

an M.D. from Brown University and completed fellowships in hematology/oncology at Brown University and Temple University.

Biopharmaceutical **POOL**

Ashleigh **PALMER**

Unigene Announces CEO Transition



Unigene Laboratories, a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs, has named Ashleigh Palmer president and CEO. Mr. Palmer previously served as CEO of Critical Biologics. He received an MBA from the University of Bradford in the United Kingdom.

Dr. Ed **SCHNIPPER**

Bind Biosciences Names Chief Medical Officer



Bind Biosciences, a privately held biopharmaceutical company developing therapeutics based on its proprietary targeted nanotechnology platform, has named Ed Schnipper, M.D., chief medical officer. Dr. Schnipper has more than 20 years of leadership experience and was most recently a VP of clinical development at Alza. He received an M.D. from the Georgetown University School of Medicine and completed fellowships in hematology at New York University and in medical oncology at Memorial Sloan-Kettering Cancer Center.

Dr. Steven **SCHOENFELD**

CalciMedica Appoints Development VP

CalciMedica, a biopharmaceutical company dedicated to the discovery and development of novel drugs for the treatment of autoimmune and inflammatory diseases, has named Steven Schoenfeld, M.D., VP, clinical development. As clinical development lead, Dr. Schoenfeld's priority is advancing the company's first calcium release-activated calcium channel inhibitor product candidate through investigational new drug (IND) application filing and into clinical development.

Before joining CalciMedica, Dr. Schoenfeld



was VP for clinical and regulatory affairs at CovX Research and, through an acquisition by Pfizer, served as executive director for biotherapeutics clinical development with Pfizer's biotherapeutics division. He received an M.D. from New York Medical College, completed his residency in internal medicine at the Westchester County Medical Center in Valhalla, New York, and completed fellowship training in endocrinology at the University of Washington in Seattle.

Specialty **POOL**

Jean-Louis **ANSPACH**

Eurand Taps Former Solvay Executive to Lead U.S. Business

Amsterdam-based global specialty pharmaceutical company Eurand NV has named Jean-Louis Anspach as president of its U.S.-based Eurand Pharmaceuticals commercial operations. Mr. Anspach was most recently executive VP, marketing, at Solvay Pharmaceuticals, which was acquired by Abbott Laboratories in February 2010. He received an MBA from the University of Wisconsin.



Chris **DAX**

Dr. Doral **FREDERICKS**

Jane Pritchett

HENDERSON

Ista Strengthens Leadership

Ista Pharmaceuticals, an ophthalmic pharmaceutical company, has expanded its senior executive team with three key hires. Chris Dax has been named VP of marketing. Mr. Dax was previously senior VP of Elan's autoimmune business. He earned an MBA from Case Western Reserve University.

Doral Fredericks, Pharm.D., has joined Ista as VP of medical affairs, from Novartis Pharmaceuticals, where she was VP of field medical affairs. Dr. Fredericks received a Pharm.D. and an MBA from a joint program at the University of Southern California.

Jane Pritchett Henderson has been appoint-





ed VP of business development for Ista. Ms. Henderson was most recently chief financial officer and executive VP, business development, for Axerion Therapeutics.

Generic POOL

Dr. Shankar **HARIHARAN**

Amneal Appoints Scientific Chief



Shankar Hariharan, Ph.D., has joined Amneal Pharmaceuticals as chief scientific officer/executive VP of specialty pharmaceuticals. Dr. Hariharan oversees all R&D, regulatory affairs, and specialty pharmaceuticals operations for Amneal, a developer, manufacturer, and distributor of generic pharmaceuticals.

Most recently, Dr. Hariharan was president, CEO, and co-founder of DermAct Pharmaceutical and Action Medicines of Spain. He received a master of pharmacy from Banaras Hindu University in Varanasi, India, and a Ph.D. from Northeastern University's School of Pharmacy.

Agency POOL

Laura **BAUMANN**

Joe **BEDNARSKI**

Cara **COCROFT**

Donald **HANSON**

Patti **KURTZ**

Pat **PAPPAGEORGE**

Tom **RAINEY**

Michelle **RIGOT**

Myra **TEJADA**

Lisa **TOTINO**

AbelsonTaylor Adds, Promotes Staff

Independent healthcare advertising agency AbelsonTaylor has made a number of additions and promotions to its creative and account groups.

Laura Baumann has been promoted to account supervisor from senior account executive, with responsibility for communications to healthcare professionals for an infant formula. She holds a master of science in integrated marketing communications and an MBA, both from Loyola University Chicago Graduate School of Business.

AbelsonTaylor has hired Joe Bednarski as senior art director. Mr. Bednarski was previously associate creative director with Fathom Advertising.

Cara Cocroft has rejoined AbelsonTaylor as account supervisor after a three-year stint as VP, account director, with Burrell Communications. Ms. Cocroft is working on pediatric and diabetes nutrition products. She has an MBA from the University of Michigan.

Donald Hanson has been promoted to account supervisor from senior account executive. Mr. Hanson is working on a gastrointestinal product and is responsible for the planning and execution of a product launch in Canada.

AbelsonTaylor has promoted Patti Kurtz to account executive from assistant account executive, with responsibility for products in the oncology direct-to-consumer area.

Pat Pappageorge has been named senior account supervisor responsible for accounts in the area of nutritional drinks. Ms. Pappageorge previously worked as an independent consultant for healthcare and nonprofit organizations. She founded CulturalBridge Wilmette, a nonprofit organization that provides academic and social resources to refugee families in the United States, which she continues to run.

Tom Rainey has joined AbelsonTaylor as account director. Mr. Rainey is working on a product for the acute treatment of migraine headaches, as well as new business opportunities. He was most recently area business director for Wyeth's Chicago office.

Michelle Rigot has joined AbelsonTaylor as copywriter, working on products in the areas of neurology, ophthalmology, and urology. She was previously copywriter for Topin & Associates.

Myra Tejada has been named account



supervisor responsible for a product in the immunology category. Ms. Tejada rejoins AbelsonTaylor after two years at Cline Davis Mann, where she was an account supervisor.

Lisa Totino has been appointed senior account supervisor, social strategy, working on the full spectrum of agency accounts. She was most recently a strategist for WhittmanHart Interactive. She received an MBA in international marketing from the Thunderbird School of Global Management.

Pamela **BOWLWARE**

Purohit Navigation Names Account Services Director



Pamela Boulware has joined full-service, independent healthcare brand solutions agency Purohit Navigation as director, account services. Ms. Boulware is responsible for executing creative campaigns and marketing programs across integrated media platforms.

Before joining Purohit, she worked as executive VP of client services at Stinson Brand Innovation and VP of client services with the Hamilton Communications Group.

Susan **DORFMAN**

CMI Appoints VP



Communications Media (CMI), which includes the CMI, Compas, and Singularity family of companies, has appointed Susan Dorfman senior VP, ByDoctor and data assets. CMI facilitates dialogue among clients, healthcare providers, patients, and caregivers.

Dr. Benny **GRANELLI**

Altum Expands Communications Staff



Altum, a CommonHealth freestanding, full-service professional advertising company, has appointed Benny Granelli, Ph.D., associate director of scientific communications. Dr. Granelli was scientific manager at ProHealth, a full-service promotional medical education division of DraftFCB Healthcare.



John **HAMILTON**

Joe **SOTO**

MicroMass Adds Account VPs



Healthcare behavioral marketing agency MicroMass Communications has appointed John Hamilton VP, group account director, responsible for spearheading the agency's oncology business. Mr. Hamilton was most recently group account director for G2. He holds an MBA from the Robert H. Smith School of Business at the University of Maryland.



Joe Soto has joined MicroMass as executive VP, director of account management. Mr. Soto was previously general manager of Nitrogen, formerly Dorland Global. He earned a master's degree in business administration from Webster University.

Tina **HO**

HC&B Expands Interactive Art Team



Independent agency HC&B Healthcare Communications has appointed Tina Ho as interactive art director. Ms. Ho is responsible for planning and designing artwork for interactive projects across all of the agency's categories and clients. She was previously senior designer at Schematic.

Greg **LEWIS**

DKI Direct Hire Marketing Chief



Patient relationship marketing agency DKI Direct has named Greg Lewis chief marketing officer. Mr. Lewis is leading and building the marketing efforts for both existing and new clients and strategically partnering with customers to ensure program quality and excellence.

Thomas **MILLAR**

EvoLogue Names Creative Chief

EvoLogue, a full-service consumer agency of CommonHealth, has named Thomas Millar executive VP, chief creative officer. Mr. Millar has direct responsibility for the overall management and productivity of the EvoLogue creative team, and he is also assisting with



client relationship-building and new business development for the consumer group.

Mr. Millar was executive VP, executive creative director at Ogilvy Healthworld.

Mike **WEISS**

D&R Communications Hires Sales VP



D&R Communications, a direct marketing agency producing initiatives for pharmaceutical manufacturer, biotech, and device industry clients, has named Mike Weiss VP, sales. Mr. Weiss' responsibilities include leading the business development team, supporting sales efforts, implementing new sales processes, managing business partner relationships, and coordinating all sales activity for greater efficiency. He was previously executive VP of sales & marketing for The Kinetix Group.

Consulting **POOL**

Michael **DOUGHERTY**

Huron Strengthens Health and Education Segment



Huron Consulting Group has appointed Michael Dougherty as managing director within the company's health and education consulting segment. Mr. Dougherty is leading the expansion of the company's compliance and investigative service offerings to the healthcare provider market.

Mr. Dougherty comes to Huron from Acuity, a firm he founded in 2006. Huron and Acuity have worked together since forming an alliance in 2008.

Katy **HEWETT**

MBS/Vox Adds to Analyst Group



MBS/Vox, a research-based consultancy unit of CommonHealth specializing in the linguistic analysis of healthcare communication, has hired Katy Hewett as a senior analyst. Ms. Hewett is responsible for analyzing data from naturally occurring healthcare interactions using soci-

olinguistic research methods and performing ethnographic research across various disease states and therapeutic areas. Ms. Hewett has a master's degree in sociolinguistics.

Lori **QUEISSER**

Former Schering-Plough Executive Joins PricewaterhouseCoopers



Lori Queisser has joined PricewaterhouseCoopers' governance, risk, and compliance practice as a senior advisor to the firm's pharmaceutical and life-sciences clients.

In addition to providing strategic guidance on compliance issues, Ms. Queisser is advising PWC on thought leadership related to strategic changes occurring in the pharmaceutical and life-sciences industry. She was most recently senior VP, global compliance and business practices, at Schering-Plough.

CRO **POOL**

Paul **COLVIN**

Dr. Mike **WILKINSON**

PPD Promotes Two VPs



PPD has named Paul Colvin executive VP of global clinical development, with particular focus on the company's global Phase II through Phase IV operations. Mr. Colvin previously served as senior VP of clinical development for North America.



Mr. Colvin succeeds Mike Wilkinson, Ph.D., who has been appointed executive VP and chief information officer. Dr. Wilkinson

also is overseeing the integration of technology initiatives with process improvement, business analytics, and global training programs.

Dr. Robert **MALONE**

Dr. Alison **MARTIN**

Beardsworth Consulting Expands Vaccines, Oncology Teams

Beardsworth Consulting Group, a privately held CRO focused on trials in complex therapeutic areas, has appointed Robert Malone,



M.D., medical director, vaccines. Dr. Malone is known as one of the original inventors of DNA vaccination.



Alison Martin, M.D., has joined Beardsworth as scientific advisor, oncology, from the National Cancer Institute, where she was head of genitourinary cancers and melanoma therapeutics. Dr. Martin was a team leader in the Office of Oncology Drug Products at the U.S. Food and Drug Administration and has experience working with the biotechnology and pharmaceutical industries.

Brenda REESE

DSP Clinical Research Names VP



DSP Clinical Research, a full-service CRO specializing in small to midsize pharmaceutical and biotech clinical trial management, has promoted Brenda Reese to VP of business operations, from executive director of West Coast operations. A registered nurse, Ms. Reese first joined DSP in 2007 as director of monitoring.

Dr. Tacey WHITE

GlaxoSmithKline Manager Joins Covance



Global drug development services company Covance has named Tacey White, Ph.D., director of global small animal development and reproductive toxicology in North America and Europe. Dr. White joins Covance from GlaxoSmithKline where she most recently was the manager and head of investigative teratology laboratory. She received a doctorate in toxicology from the University of Rochester.

Medical-Education POOL

Jessica GUNTER

Dr. Stephen MOTTOLA

HLS Announces Two Promotions

HLS, CommonHealth's medical-education unit, has promoted Jessica Gunter to research manager from research coordinator. Ms.

Gunter is responsible for overseeing the maintenance of reference libraries and copyright permissions.



Stephen Mottola, Pharm.D., has advanced to senior medical writer from his previous position as medical writer. Mr. Mottola is responsible for writing primary and review manuscripts.

Service POOL

Frank ARENA

Former Novartis Sales VP Joins PDI



Frank Arena has been named senior VP of commercial operations for PDI. Mr. Arena is responsible for integrating the operations of PDI's promotional outsource services, including pharmaceutical sales teams and medical communication programs. He was most recently VP sales, center of excellence, for Novartis.

Judy BERWICK

MediciGlobal Expands Account Team



MediciGlobal, a specialty patient recruitment and retention company, has hired Judy Berwick as account executive, with initial responsibility for projects involving women's health, pediatrics, and CNS. Ms. Berwick joins the MediciGlobal team from PharmaNet.

Technology POOL

Elaine BOXER

Amit CHATURVEDI

Denise ESAKOFF

Virginia (Ginger) EVANS

Chris NEUNER

Louis SANQUINI

QualityHealth Strengthens Executive Team

QualityHealth, a targeted online customer

acquisition solution for healthcare marketers, has added several VPs. As part of this effort, QualityHealth has named Elaine Boxer senior VP, marketing strategy. Ms. Boxer was most recently VP client partner at Avenue A|Razorfish. She holds an MBA from the Wharton School of the University of Pennsylvania.

Amit Chaturvedi has been appointed senior VP, chief operating officer. Mr. Chaturvedi joins QualityHealth from IAC Advertising Solutions, where he served as senior VP of operations.

Denise Esakoff has been named VP, product management. Ms. Esakoff has experience in research, analysis, product marketing, and brand management for Novartis and GlaxoSmithKline.

As senior director, marketing analytics, Virginia (Ginger) Evans brings measurement analytics and insights from her experience with inVentiv Advance Insights and Cephalon. Ms. Evans is helping to give brand marketers access to in-depth strategic and tactical analytics.

Chris Neuner has joined QualityHealth as executive VP, sales and client engagement. Mr. Neuner leads the company's client-facing teams. He was previously CEO of Greater Than One.

Louis Sanquini has been named VP, product innovation. Mr. Sanquini's diverse pharmaceutical experience includes numerous product successes at both GlaxoSmithKline and Meda Pharmaceuticals.

Amanda MACKEDANZ

Deacom Adds Senior Product Consultant



Deacom, producer of the Deacom Integrated Accounting and Enterprise Resource Planning Software System for mid-to-large-sized pharmaceutical manufacturers, has hired Amanda Mackedanz as a senior product consultant. Ms. Mackedanz, formerly with ProcessPro Software, is responsible for working with manufacturing companies in determining their business process. ♦

Send your personnel announcements to feedback@pharmavoices.com.

SEE DIGITAL EDITION FOR BONUS CONTENT
WWW.PHARMAVOICE.COM

TALENT pool

Pharmaceutical **POOL**Dr. Toshihiro **HOSAKA**Dr. Roland **NEWMAN**Dr. Masaki **YAMADA**

Tanabe Research Labs USA Begins New Operations at San Diego Facility

Tanabe Research Labs USA (TRL) has appointed three new senior executives as part of its relaunch of operations at the TRL facility in San Diego with a focus on biological drugs for the treatment of autoimmune diseases.

Toshihiro Hosaka, Ph.D., has been appointed senior VP of TRL. Dr. Hosaka entered the pharmaceutical industry in 1993 as a medicinal chemist and project manager for Tanabe Seiyaku, the predecessor to Mitsubishi Tanabe Pharma Corporation (MTPC), TRL's parent corporation. He earned a Ph.D. in synthetic organic chemistry from Chiba University in Japan and was a visiting scholar at Stanford University in 1998.

Roland Newman, Ph.D., has been named VP and chief scientific officer. Dr. Newman has more than three decades of experience in biochemistry, immunology, and molecular biology research and business development in both academic and commercial settings, and is the co-inventor and co-developer of Rituxan and other antibody-based therapeutics. Before joining TRL, he served as principal at Rana Consulting.

Dr. Newman obtained a Ph.D. at the University of Bath in the United Kingdom and did postdoctoral research at the Imperial Cancer Research Fund laboratories in London and the University Medical Clinic in Cologne, Germany.

Masaki Yamada, Ph.D., has been named president and CEO of TRL. Dr. Yamada joined the predecessor to MTPC in 1985 and most recently managed research projects, portfolio, and alliances within MTPC.

Dr. Michael **MENDELSON**

Tufts Veteran Joins Merck as Head of Cardiovascular Research

Michael Mendelsohn, M.D., has been appointed senior VP of Merck Research Laboratories and franchise head, atherosclerosis and cardiovascular research. Dr. Mendelsohn's responsibilities include overseeing Merck's scientific direction across the full spectrum of

drug discovery and development through clinical trials for atherosclerosis and cardiovascular research.

Dr. Mendelsohn joins Merck after 17 years at Tufts Medical Center in Boston, where he most recently served as chief scientific officer. He received a medical degree from Harvard Medical School and is board-certified in internal medicine and cardiovascular disease.

Biotechnology **POOL**Dr. John **HEY**

NormOxys Names Early Development VP

NormOxys, a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, has named John Hey, Ph.D., senior VP of preclinical and early development. Dr. Hey's responsibilities include working closely with the NormOxys management team to support the advancement of clinical lead OXY111A, in development for the treatment of chronic heart failure and cancer. A biotech executive with more than 20 years of drug discovery and development experience, Dr. Hey joins NormOxys from CoMentis, where he served as senior VP, discovery and preclinical drug development.

Dr. Catharine **JOHNSON**

aTyr Pharma Adds Business Development Executive

Catharine Johnson, Ph.D., has joined aTyr Pharma as senior VP of business development, using her extensive biotechnology industry experience to help advance the privately held biotech company's portfolio of resectin-based therapeutics. Resectins are a novel class of endogenous human proteins derived from aminoacyl tRNA synthetases and have activities relevant to multiple disease areas, including autoimmunity, inflammation, and blood disorders.

Dr. Johnson was VP, corporate development, Momenta Pharmaceuticals. She received a doctorate from the Johns Hopkins School of Medicine's Department of Biological Chemistry.

Claire **LOCKEY**

Relypsa Taps Regulatory Affairs VP

Claire Lockey has joined Relypsa as VP,

regulatory affairs. Relypsa is a privately held, development-stage biopharmaceutical company leading the discovery and development of non-absorbed polymeric drugs for application in cardiovascular and renal diseases.

Ms. Lockey is responsible for overseeing Relypsa's regulatory affairs, quality assurance, and related project management, with initial focus on the clinical development of lead product candidate RLY5016, a potassium binder for the management of hyperkalemia.

Ms. Lockey was previously VP, regulatory affairs for Fibrogen.

Dr. Michael **MORRISSEY**

Exelixis Announces CEO Transition

Exelixis, a development-stage biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases, has promoted Michael Morrissey, Ph.D., to president and CEO. Dr. Morrissey succeeds George Scangos, Ph.D., who has left Exelixis to become president and CEO of Biogen Idec.

Dr. Morrissey joined Exelixis in 2000 and has served as president of research and development since January 2007. He received a Ph.D. in chemistry from Harvard University.

James **SHIELDS**

Spectrum Names Commercial Chief

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a focus in oncology and hematology, has appointed James Shields senior VP and chief commercial officer. Mr. Shields' oncology sales experience includes positions as VP of sales for oncology and injectable products for MGI Pharmaceuticals and VP of sales and marketing of oncology for SuperGen. He joins Spectrum from Teva Pharmaceutical Industries.

Biopharmaceutical **POOL**Dr. Geoffrey **NICHOL**

Ikaria Names Medical Chief

Ikaria has appointed Geoffrey Nichol, M.D., chief medical officer, with responsibility for activities related to late-stage drug development. Ikaria is a biotherapeutics company focused on developing and commercializ-

ing therapeutics and interventions designed to address significant unmet needs of critically ill patients

Dr. Nichol has more than two decades of pharmaceutical industry experience, most recently as senior VP of product development for Medarex.

Gary ZIEZIULA

Amag Pharmaceuticals Appoints
Commercial Chief

Amag Pharmaceuticals has named Gary Zieziula as executive VP and chief commercial officer. Mr. Zieziula is responsible for leading Amag's global commercial strategy in support of the planned label expansion for Feraheme (ferumoxyl) Injection for intravenous use across all therapeutic indications and imaging applications, as well as evaluating the commercial attractiveness of potential in-licensing opportunities. Amag is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia.

Mr. Zieziula was most recently managing director, pharmaceuticals, for Roche (Hellas) S.A. in Greece. He received an MBA from Canisius College.

Specialty POOL

Douglas BAUM

Dr. Danny KAO

TheraQuest Adds Development VPs

TheraQuest Biosciences, a clinical-stage pain management company, has named Douglas Baum senior VP, business development. Mr. Baum has been involved in analgesic drug development for more than 20 years, serving as VP, strategic development, in the analgesia and rheumatology group at Scirex, and later as senior VP, early development unit and VP, global business development, with Premier Research Group. He has authored more than 20 scientific publications in the field of pain and holds an M.S. from the University of Texas at Austin.

TheraQuest also has announced the appointment of Danny Kao, Ph.D., as senior VP, pharmaceutical development and general counsel. Dr. Kao joins TheraQuest from Endo Pharmaceuticals, where he was director, strategic development and director, formulation development. He received a master's degree in

industrial pharmacy from St. John's University, a Ph.D. in pharmaceutical sciences from the University of Kentucky, and a J.D. from Touro College Law Center. Dr. Kao is a registered patent attorney at the U.S. Patent and Trademark Office and is admitted to practice law in New York and New Jersey.

Drug-Delivery POOL

Dr. Eric DADEY

MonoSol Rx Names Development VP

MonoSol Rx, a specialty pharmaceutical company leveraging its proprietary Pharm-Film technology to deliver proprietary pharmaceutical drug films, has appointed Eric Dadey, Ph.D., senior VP, pharmaceutical development. Dr. Dadey was most recently VP, preclinical development, at Transave Inhalation Biotherapeutics. He holds an M.S. in chemistry at Western Kentucky University, and an M.S. in organic chemistry and a Ph.D. in pharmaceutical sciences, both from the University of Kentucky.

Device/Diagnostic POOL

Gary KING

Myriad Genetics Taps International
Operations VP

Molecular diagnostics company Myriad Genetics has named Gary King executive VP of international operations, responsible for overseeing all aspects of the company's expansion into Europe and other international markets. Mr. King received an MBA from Stanford University.

Agency POOL

Tim BASILICA

Kris POLLINA

Melanie SAMSON

John THELIAN

LyonHeart Communications has announced

several additions to its team. Tim Basilica has joined the agency as an art supervisor. Kris Pollina has been appointed a VP, group copy supervisor. Melanie Samson has been named an account supervisor. John Thelian has been hired as an art group supervisor.

David GAGLIANO

Access Communications Promotes CEO

Access Communications has named Chief Financial Officer David Gagliano to president and CEO. The strategic healthcare communications agency network had been under the leadership of a group of managing partners that included Mr. Gagliano since mid-2009.

Consulting POOL

William (Billy) HOLDEN

ParagonRx Names Chief Safety Officer

ParagonRx, an inVentiv Health consulting company specializing in pharmaceutical risk management and optimizing medication, has appointed William (Billy) Holden chief safety officer. Mr. Holden has almost two decades of experience working at top levels for major drug companies in the areas of pharmacoepidemiology, signal detection, and risk management. He most recently served as head of pharmacoepidemiology and benefit risk management for Vertex.

Mr. Holden has a master's in epidemiology from Columbia University and a doctorate in epidemiology from Yale University.

Dr. Toby SILVERMAN

Dr. Keith WATSON

Parexel Consulting Strengthens
Regulatory Expertise

Parexel Consulting, a global life-sciences consultancy and unit of Parexel International, has appointed two former regulators as principal consultants, further expanding its global team of regulatory and product development experts to support accelerated approvals of clients' innovative biotechnology and blood product platforms.

Toby Silverman, M.D., joins Parexel Consulting after a 20-year career with the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research

TALENT pool

(CBER), where he most recently served as senior advisor in the Office of Blood Research and Review.

Before joining Parexel Consulting, Keith Watson, Ph.D., was with The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom, where he was engaged with key biotechnology advisory groups in Europe.

CRO POOL

Dr. Mary SPELLMAN

Integrium Adds Dermatology Research Group

Integrium, a CRO specializing in cardiovascular and metabolic disease, has expanded into dermatology with the addition of a dedicated Dermatology Clinical Research Group led by Mary Spellman, M.D.

Dr. Spellman is a board-certified dermatologist with 20 years of experience in clinical research and drug and medical device development, most recently as chief medical officer for Revance Therapeutics. In addition to working with Integrium, Dr. Spellman maintains a pharmaceutical and medical device consulting practice. She earned a medical degree from the Medical College of Wisconsin.

Hani ZAKI

PRA International Adds to Late-Phase Services Leadership

PRA International has named Hani Zaki senior VP of its late-phase services group, which is focused on successful postapproval activities. Most recently, Mr. Zaki served as corporate VP and general manager for another major CRO's postapproval division. He received an MPH in epidemiology from the Tulane University School of Public Health and Tropical Medicine and an MBA in pharmaceutical marketing from St. Joseph's University.

Media POOL

Kathy CHRISTIE

Carol NATHAN

Quadrant HealthCom Adds, Promotes Managers

Quadrant HealthCom (QHI), a multimedia communications company specializing in the healthcare market, has appointed Kathy Christie, editorial manager, custom programs. Ms. Christie serves as managing editor of Sexuality, Reproduction, and Menopause (SRM),

an ongoing quarterly publication of the American Society for Reproductive Medicine, and is also working on other custom programs. She joins QHI from Haymarket Medical Education, where she worked as an in-house freelance project editor.

QHI also has promoted Carol Nathan to VP, custom programs, from her previous role as editor of QHI's The Female Patient. Ms. Nathan is responsible for overseeing content development and ensuring best practices are maintained regarding the development and management of custom programs created for QHI clients.

Service POOL

Frank IORIO

CGS VirtualEvents365 Appoints Health Sciences Director

Healthcare publishing and communications industry veteran Frank Iorio has joined Computer Generated Solutions and its VirtualEvents365 business unit as director of health sciences virtual solutions. Mr. Iorio is leading business development efforts for the company's integrated online event technology.

Mr. Iorio has served in a variety of senior-level positions in the healthcare publishing and communications sectors. ♦

Searching for the right audience for your next e-mail campaign?

Target PharmaVOICE Readers with your E-mail Marketing Campaign

- Segment our opt-in e-mail database of 65,000+
- 20% off multiple emails
- 50% off all resends
- Best practices for better ROI
- Design and html coding available

Call 215-321-8656 or e-mail mwalsh@pharmavoices.com to discuss your next email promotion with Marah Walsh.

Pharma**VOICE**





QUALITY OVERSIGHT OF CLINICAL VENDORS

Strategies for Assessing and Managing Quality at CROs & other Specialty Providers

October 12-14, 2010 • Westin Arlington Gateway • Arlington, VA

- ✦ Identify your outsourcing risks
- ✦ Recognize your responsibilities
- ✦ Clarify your expectations
- ✦ Remain inspection ready

KEYNOTE:

**Oversight of Outsourced Work:
A Review of Transfer of Obligations,
Sponsor Responsibility and the FDA's
Risk-Management Approach to Inspections**

Leslie K. Ball, MD, CAPT, USPHS,
*Director, Division of Scientific Investigations,
Office of Compliance, CDER,
FDA (invited)*

Featured Presentations Addressing:

Inspection Findings	Quality-to-Quality Interaction
Recent Warning Letters	Designing and Evaluating Monitoring Plans
Vendor Selection	Oversight in Emerging Regions
Quality Agreements	Audits to Measure Performance
Establishing Expectations at Project Kick-Off	The Clinical QA/Clinical Operations Partnership
Protocol Complexity Risk	Quality Management Case Studies
Issue Escalation	...and more!

TO REGISTER Call **866-207-6528** or visit us at www.exlpharma.com/qualityoversight

Conference Sponsors:



With Support from:



Save
10% off
your
registration rate.

Simply enter **exlpvad**
when registering

With Support from:



JOURNAL FOR
CLINICAL STUDIES
Your Resource for Multisite Studies & Emerging Markets

Take Advantage Of
In-Depth Half-Day
Workshops On:

A Organizing Your
Clinical Trial Data for
Better Utilization and
Decision-Making

B Quality Oversight
of Clinical Vendors



The only event designed to address GCP compliance challenges from a strategic, senior level

European Proactive GCP Compliance

Building in Quality to Meet New Requirements and Ensure Patient Safety

October 18-20, 2010 | Hilton Berlin | Berlin, Germany

Address the Shift in GCP Enforcement Priorities and Enforcement Focus by:

- Driving your business effectively in a new enforcement environment
- Preparing for a collaborative auditing experience between the FDA and EMA
- Evolving from traditional QA to a quality management culture
- Interpreting and applying the regulatory nuances and ethics of emerging regions
- Ensuring the right mechanisms are in place for effective oversight
- Avoiding over- or under-interpreting the regulations
- Committing to the best processes and smartest use of your resources
- Recognizing compliance gaps across a study or system
- Learning how to look for patterns in deviations and where more training is needed
- Sharing your experiences by actively participating in sessions as well as end-of-day roundtable discussions

TO REGISTER Call **+1-212-400-6240** or visit us at www.exlpharma.com/EuroGCP